| URL | https://endpts.com/covid-19-roundup-pfizer-lands-m |
| Source | Endpoints News |
| Date Published | 11/18/2021 |
| Author Name | Zachary Brennan |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Pfizer |
| Parent company | Pfeizer |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2011 |
| Domestically, the work will be done: | In-house |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Pfizer pill to treat Covid-19 |
| What domestic positive factors made reshoring more attractive? | Government Incentives |
| Government Incentive dollar amount: | $5.29 billion |